Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) CEO Robert I. Blum sold 11,500 shares of Cytokinetics stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $59.49, for a total value of $684,135.00. Following the sale, the chief executive officer now owns 399,412 shares of the company’s stock, valued at approximately $23,761,019.88. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Cytokinetics Stock Down 1.9 %
Shares of CYTK stock traded down $1.15 during trading hours on Wednesday, hitting $59.01. 1,321,481 shares of the company were exchanged, compared to its average volume of 2,502,568. The firm has a market cap of $6.19 billion, a PE ratio of -11.14 and a beta of 0.75. Cytokinetics, Incorporated has a 1 year low of $25.98 and a 1 year high of $110.25. The firm has a fifty day moving average of $53.96 and a 200 day moving average of $65.24.
Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.17). The firm had revenue of $0.84 million for the quarter, compared to the consensus estimate of $0.91 million. During the same quarter in the prior year, the company earned ($1.38) EPS. The firm’s revenue for the quarter was down 81.8% on a year-over-year basis. Analysts expect that Cytokinetics, Incorporated will post -4.5 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on CYTK
Hedge Funds Weigh In On Cytokinetics
Several institutional investors have recently modified their holdings of CYTK. HealthInvest Partners AB bought a new stake in Cytokinetics during the fourth quarter worth approximately $980,000. Vestal Point Capital LP bought a new stake in Cytokinetics in the 4th quarter valued at $4,174,000. Victory Capital Management Inc. grew its holdings in Cytokinetics by 1,040.4% in the 4th quarter. Victory Capital Management Inc. now owns 191,654 shares of the biopharmaceutical company’s stock valued at $16,001,000 after buying an additional 174,848 shares in the last quarter. State of Michigan Retirement System acquired a new stake in Cytokinetics in the first quarter valued at about $1,690,000. Finally, Louisiana State Employees Retirement System bought a new position in shares of Cytokinetics during the fourth quarter worth about $4,099,000.
Cytokinetics Company Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
See Also
- Five stocks we like better than Cytokinetics
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- Using the MarketBeat Dividend Tax Calculator
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- Find and Profitably Trade Stocks at 52-Week Lows
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.